Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Marc Evans1, Aled Roberts, Steve Davies

  • 1Department of Metabolic Medicine, Diabetes and Endocrinology, University of Wales College of Medicine, Cardiff, Wales. marc.evans2@ntlworld.com

Drugs
|May 27, 2004
PubMed
Summary

Intensive reduction of low-density lipoprotein-cholesterol (LDL-C) significantly lowers coronary heart disease (CHD) risk. Newer statins and therapies targeting HDL-C and inflammation offer improved lipid management and cardiovascular risk reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same author

Cardiovascular-Kidney-Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling.

Diabetes, obesity & metabolism·2026
Same author

Validation of the Obesity Lifecycle Model Built to Assess the Cost Effectiveness of Novel Therapies in the Management of Obesity.

PharmacoEconomics - open·2026
Same author

Estimating the Future Health and Social Care Costs of Alzheimer's Disease Dementia in the UK: Impact of Disease Modifying Therapy Efficacy, Uptake, and Care Model - A Scenario Modelling Study.

International journal of geriatric psychiatry·2026
Same author

Developing a Comprehensive Approach for Managing Cardiorenal Metabolic Diseases (CRMD) in Saudi Arabia: Thinking beyond Single Disease-Literature Review and Multidisciplinary Consensus Report.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2025
Same author

Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus.

Diabetes, obesity & metabolism·2025

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Coronary heart disease (CHD) is a leading cause of global mortality.
  • Elevated low-density lipoprotein-cholesterol (LDL-C) and low high-density lipoprotein-cholesterol (HDL-C) are established CHD risk factors.
  • Current treatment guidelines may under-treat patients, necessitating revised targets.

Purpose of the Study:

  • To review the evidence for intensive LDL-C reduction in managing CHD.
  • To discuss the role of emerging therapies and lipid targets in cardiovascular risk reduction.
  • To highlight the importance of HDL-C and anti-inflammatory effects in atherogenesis.

Main Methods:

  • Review of clinical trial data on statins and other lipid-modulating agents.
  • Analysis of current and proposed treatment guidelines for cholesterol management.

Related Experiment Videos

  • Examination of studies investigating HDL-C and novel therapeutic targets.

    • Main Results:

    • Intensive LDL-C reduction, even to levels as low as 1.7 mmol/L, is associated with significant clinical benefit.
    • Newer statins like rosuvastatin demonstrate high efficacy in achieving LDL-C targets.
    • Raising HDL-C and addressing inflammation are emerging as crucial strategies for CHD prevention.

    Conclusions:

    • Lowering LDL-C is a cornerstone of CHD risk reduction, with evidence supporting more aggressive targets.
    • Novel pharmacological agents offer improved lipid profile optimization and potential pleiotropic benefits.
    • A comprehensive approach targeting LDL-C, HDL-C, and inflammation is essential for effective cardiovascular risk management.